Form 4: Spyre Therapeutics CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Cameron Turtle, Chief Executive Officer and a Director of Spyre Therapeutics, Inc., sold 15,000 shares of common stock on August 3, 2026.

Summary

  • Open-market sale: disposed of 800 Common Stock at $93.97 ($75,176) on August 3, 2026; holds 581,740 after (Direct).
  • Open-market sale: disposed of 7,157 Common Stock at $95.10 ($680,631) on August 3, 2026; holds 574,583 after (Direct).
  • Open-market sale: disposed of 5,635 Common Stock at $95.93 ($540,566) on August 3, 2026; holds 568,948 after (Direct).
  • Open-market sale: disposed of 1,392 Common Stock at $96.82 ($134,773) on August 3, 2026; holds 567,556 after (Direct).
  • Open-market sale: disposed of 16 Common Stock at $97.46 ($1,559) on August 3, 2026; holds 567,540 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,432,705 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Cameron Turtle — Director, Officer (Chief Executive Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-03Open-market saleCommon Stock800$94$75.2K581,740
2026-08-03Open-market saleCommon Stock7,157$95$680.6K574,583
2026-08-03Open-market saleCommon Stock5,635$96$540.6K568,948
2026-08-03Open-market saleCommon Stock1,392$97$134.8K567,556
2026-08-03Open-market saleCommon Stock16$97$1.6K567,540

Key Dates

DateDescription
2026-08-03Open-market sale (800 shares)
2026-08-03Open-market sale (7,157 shares)
2026-08-03Open-market sale (5,635 shares)
2026-08-03Open-market sale (1,392 shares)
2026-08-03Open-market sale (16 shares)

Keywords

insider transaction, Form 4, SYRE, Spyre Therapeutics, Inc., bearish, Cameron Turtle

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.